BRCA1 and BRCA2 carriers with no history of cancer had low baseline decisional conflict about breast risk management options in intervention and control groups, which declined with time up to 12-months and was not significantly influenced by a paper-based ptDA used at home after post-test genetic counselling (55). This evidence concerns the gene BRCA2 and cancer.